Nektar Therapeutics | NKTR - Stock


Nektar Therapeutics reported $14.46M in Stock for its fiscal quarter ending in June of 2024.





Stock Change Date
Agios Pharmaceuticals USD 32.92M 886K Dec/2025
ALKERMES USD 196.62M 5.63M Dec/2025
Amgen USD 6.22B 121M Dec/2025
Baxter International USD 2.23B 228M Dec/2025
BioCryst Pharmaceuticals USD 5.4M 166K Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Cara Therapeutics USD 900K 0 Mar/2025
Cipla INR 61.6B 5.18B Sep/2025
Dr.Reddys Laboratories INR 79.01B 3.19B Dec/2025
Eisai JPY 236.46B 9.14B Sep/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Exelixis USD 27.4M 3.92M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
GlaxoSmithKline GBP 6.12B 46M Sep/2025
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 176.48M 9.32M Dec/2025
Incyte USD 101.06M 17.61M Dec/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 7.91M 840K Dec/2025
Merck USD 6.44B 157M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
Takeda JPY 1.41T 107.71B Dec/2025
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025